This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shahmanesh, M. Articles by Umpleby, A. M. Search for Related Content PubMed PubMed Citation Articles by Shahmanesh, M. Articles by Umpleby, A. M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information AIDS Medicines Related Collections Lipid

Antiretroviral Treatment Reduces Very-Low-Density Lipoprotein and Intermediate-Density Lipoprotein Apolipoprotein B Fractional Catabolic Rate in Human Immunodeficiency Virus-Infected Patients with Mild Dyslipidemia

Departments of HIV and Chemical Pathology (M.Sh., S.D., R.C., P.N.), University Hospitals Birmingham, Birmingham B29 6JF, United Kingdom; and Department of Diabetes and Endocrinology (M.St., F.S.-M., N.C.J., W.J., A.M.U.), St. Thomas’ Hospital, GKT School of Medicine, Kings College, London, SE1 7EH, United Kingdom

Address all correspondence and requests for reprints to: Margot Umpleby, Department of Diabetes and Endocrinology, 4th Floor, N Wing, St. Thomas Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom. E-mail: margot.umpleby{at}kcl.ac.uk.

The relationship between antiretroviral treatment of HIV infection, body fat distribution, insulin resistance, and very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) apolipoprotein-B (apoB) kinetics was investigated in 55 HIV-infected patients taking two nucleoside analogs plus either a protease inhibitor (n = 15) or a nonnucleoside reverse transcriptase inhibitor (n = 25), 15 antiretroviral therapy-naive patients, and 12 HIV-negative controls.

Compared with the controls, high-density lipoprotein cholesterol was reduced in all groups (P < 0.01). Plasma triglyceride was increased in patients taking protease inhibitors (P < 0.05). VLDL and IDL apoB fractional catabolic rate (FCR) was lower in all treatment groups (P < 0.05) compared with controls. Trunk fat, VLDL apoB absolute secretion rate, and insulin resistance were not different between groups. Peripheral fat was lower in the treated patients (P < 0.05) and correlated with duration of therapy (r = –0.55; P < 0.001). There was a positive correlation between peripheral fat and VLDL apoB FCR (P = 0.002) and IDL apoB FCR (P = 0.002) and a negative correlation with VLDL apoB pool size, VLDL cholesterol, and triglyceride (P < 0.03; P < 0.01; P < 0.002).

These results suggest that mild dyslipidemia resulting from antiretroviral therapy is caused by a decrease in VLDL and IDL apoB FCR, which is associated with a loss of peripheral fat.

This article has been cited by other articles:

				W. Guo, S. Wong, J. Pudney, R. Jasuja, N. Hua, L. Jiang, A. Miller, P. W. Hruz, J. A. Hamilton, and S. Bhasin Acipimox, an Inhibitor of Lipolysis, Attenuates Atherogenesis in LDLR-Null Mice Treated With HIV Protease Inhibitor Ritonavir Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2028 - 2032. [Abstract] [Full Text] [PDF]

				O. P. Flint, M. A. Noor, P. W. Hruz, P. B. Hylemon, K. Yarasheski, D. P. Kotler, R. A. Parker, and A. Bellamine The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications Toxicol Pathol, January 1, 2009; 37(1): 65 - 77. [Abstract] [Full Text] [PDF]

				M. A.M. den Boer, J. F.P. Berbee, P. Reiss, M. van der Valk, P. J. Voshol, F. Kuipers, L. M. Havekes, P. C.N. Rensen, and J. A. Romijn Ritonavir Impairs Lipoprotein Lipase-Mediated Lipolysis and Decreases Uptake of Fatty Acids in Adipose Tissue Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 124 - 129. [Abstract] [Full Text] [PDF]